Login:
 
Incretin-based diabetes therapy not associated with increased mortality

Incretin-based diabetes therapy not associated with increased mortality

28 Jul 2017Registered users

A recent meta-analysis, published in the BMJ, has shown no increase in all cause mortality in patients with type 2 diabetes using incretin-based treatments i.e. GLP-1 agonists and DPP-4 inhibitors.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.

To buy this article (£25+tax) copy the article citation above and click Buy article